Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
FGFR1-4 Inhibitor (Pan-FGFR TKI)

Erdafitinib

Brand names: Balversa

Erdafitinib is an oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor used to treat advanced or metastatic urothelial carcinoma harbouring susceptible FGFR genetic alterations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits FGFR tyrosine kinase activity, blocking downstream signalling that drives proliferation and survival in FGFR-altered tumour cells.

Prescribing in practice

  • Serous retinopathy and other ocular disorders can cause visual impairment, so regular ophthalmological assessment and prompt reporting of visual symptoms are essential.
  • Hyperphosphataemia is an expected on-target effect that may require phosphate management and dose modification.
  • Nail and skin disorders, stomatitis and dry mouth are common and may need supportive care.

Monitoring

Monitor serum phosphate, perform regular ophthalmic examinations, and review nail, skin and mucosal toxicity during treatment.

Counselling the patient

  • Attend all eye check-ups and report any blurred vision, distortion or other visual changes promptly.
  • Follow advice on diet and phosphate-related medicines as instructed.
  • Use mouth and skin care measures and report painful mouth ulcers or nail problems.

Evidence & guidelines

The BLC2001 trial supported erdafitinib's activity in FGFR-altered advanced urothelial carcinoma.

Reference: BLC2001 trial (Loriot et al. NEJM 2019); THOR trial; FDA approval 2019; MHRA SPC Balversa; EAU Bladder Cancer Guidelines 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways